The DOI matches its Crossref record; 304 of the 304 references it cites were found in a registry or an index.
Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives
Abstract
In the past decade, nanomedicine with its promise of improved therapy and diagnostics has revolutionized conventional health care and medical technology. Dendrimers and dendrimer-based therapeutics are outstanding candidates in this exciting field as more and more biological systems have benefited from these starburst molecules. Anticancer agents can be either encapsulated in or conjugated to dendrimer and be delivered to the tumour via enhanced permeability and retention (EPR) effect of the nanoparticle and/or with the help of a targeting moiety such as antibody, peptides, vitamins, and hormones. Imaging agents including MRI contrast agents, radionuclide probes, computed tomography contrast agents, and fluorescent dyes are combined with the multifunctional nanomedicine for targeted therapy with simultaneous cancer diagnosis. However, an important question reported with dendrimer-based therapeutics as well as other nanomedicines to date is the long-term viability and biocompatibility of the nanotherapeutics. This critical review focuses on the design of biocompatible dendrimers for cancer diagnosis and therapy. The biocompatibility aspects of dendrimers such as nanotoxicity, long-term circulation, and degradation are discussed. The construction of novel dendrimers with biocompatible components, and the surface modification of commercially available dendrimers by PEGylation, acetylation, glycosylation, and amino acid functionalization have been proposed as available strategies to solve the safety problem of dendrimer-based nanotherapeutics. Also, exciting opportunities and challenges on the development of dendrimer-based nanoplatforms for targeted cancer diagnosis and therapy are reviewed (404 references).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mammen, M., Choi, S.-K., & Whitesides, G. M. (1998) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19981102)37:20<2754::aid-anie2754>3.0.co;2-3 · Cited by 4,110
A New Class of Polymers: Starburst-Dendritic Macromolecules
Tomalia, D. A., Baker, H., Dewald, J., Hall, M., Kallos, G., Martin, S., Roeck, J., Ryder, J., & Smith, P. (1985) · Polymer Journal · doi:10.1295/polymj.17.117 · Cited by 3,904
Hawker, C. J., & Frechet, J. M. J. (1990) · Journal of the American Chemical Society · doi:10.1021/ja00177a027 · Cited by 2,413
Designing dendrimers for biological applications
Lee, C. C., MacKay, J. A., Fréchet, J. M. J., & Szoka, F. C. (2005) · Nature Biotechnology · doi:10.1038/nbt1171 · Cited by 2,043
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
Dendrimers in biomedical applications—reflections on the field
SVENSON, S., & TOMALIA, D. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.018 · Cited by 1,919
Astruc, D., Boisselier, E., & Ornelas, C. (2010) · Chemical Reviews · doi:10.1021/cr900327d · Cited by 1,844
PEGylated nanoparticles for biological and pharmaceutical applications
Otsuka, H., Nagasaki, Y., & Kataoka, K. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00226-0 · Cited by 1,588
Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications
Esfand, R., & Tomalia, D. A. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01757-3 · Cited by 1,562
Dendrimers and dendritic polymers in drug delivery
Gillies, E. R., & Fréchet, J. M. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03276-3 · Cited by 1,367
Cited by
Design of polymeric nanoparticles for biomedical delivery applications
Elsabahy, M., & Wooley, K. L. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15327k · Cited by 1,717
Sapsford, K. E., Algar, W. R., Berti, L., Gemmill, K. B., Casey, B. J., Oh, E., Stewart, M. H., & Medintz, I. L. (2013) · Chemical Reviews · doi:10.1021/cr300143v · Cited by 1,423
Applications of nanoparticle systems in drug delivery technology
Rizvi, S. A. A., & Saleh, A. M. (2018) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2017.10.012 · Cited by 1,334
Stimuli-Responsive Therapeutic Metallodrugs
Wang, X., Wang, X., Jin, S., Muhammad, N., & Guo, Z. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 649
Polymeric Conjugates for Drug Delivery
Larson, N., & Ghandehari, H. (2012) · Chemistry of Materials · doi:10.1021/cm2031569 · Cited by 580
Applications and Limitations of Dendrimers in Biomedicine
Chis, A. A., Dobrea, C., Morgovan, C., Arseniu, A. M., Rus, L. L., Butuca, A., Juncan, A. M., Totan, M., Vonica-Tincu, A. L., Cormos, G., et al. (2020) · Molecules · doi:10.3390/molecules25173982 · Cited by 467
The Future of Nanotechnology in Plant Pathology
Elmer, W., & White, J. C. (2018) · Annual Review of Phytopathology · doi:10.1146/annurev-phyto-080417-050108 · Cited by 461
Dong, H., Chen, Y.-C., & Feldmann, C. (2015) · Green Chemistry · doi:10.1039/c5gc00943j · Cited by 455
Surface-Engineered Dendrimers in Gene Delivery
Yang, J., Zhang, Q., Chang, H., & Cheng, Y. (2015) · Chemical Reviews · doi:10.1021/cr500542t · Cited by 429
Self-citationNanoparticles and its biomedical applications in health and diseases: special focus on drug delivery
Zahin, N., Anwar, R., Tewari, D., Kabir, M. T., Sajid, A., Mathew, B., Uddin, M. S., Aleya, L., & Abdel-Daim, M. M. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-019-05211-0 · Cited by 371
Progress, challenges, and future of nanomedicine
Zhang, C., Yan, L., Wang, X., Zhu, S., Chen, C., Gu, Z., & Zhao, Y. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101008 · Cited by 318
Dendrimers as Pharmaceutical Excipients: Synthesis, Properties, Toxicity and Biomedical Applications
Santos, A., Veiga, F., & Figueiras, A. (2019) · Materials · doi:10.3390/ma13010065 · Cited by 313
Simplifying the synthesis of dendrimers: accelerated approaches
Walter, M. V., & Malkoch, M. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35062a · Cited by 301
Nanotechnological carriers for cancer chemotherapy: The state of the art
Estanqueiro, M., Amaral, M. H., Conceição, J., & Sousa Lobo, J. M. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.12.041 · Cited by 298
Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancers
Li, Y., Xiao, K., Zhu, W., Deng, W., & Lam, K. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.008 · Cited by 292
Self-citationPoly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy
Li, J., Liang, H., Liu, J., & Wang, Z. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.05.045 · Cited by 281
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., & Pedraz, J. L. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0766-6 · Cited by 268
Dendrimers: A New Race of Pharmaceutical Nanocarriers
Mittal, P., Saharan, A., Verma, R., Altalbawy, F. M. A., Alfaidi, M. A., Batiha, G. E.-S., Akter, W., Gautam, R. K., Uddin, M. S., & Rahman, M. S. (2021) · BioMed Research International · doi:10.1155/2021/8844030 · Cited by 257
Teng, L., Shao, Z., Bai, Q., Zhang, X., He, Y., Lu, J., Zou, D., Feng, C., & Dong, C. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202105628 · Cited by 254
Morelli, X., Bourgeas, R., & Roche, P. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.024 · Cited by 223
Engineered nanoparticles, How brain friendly is this new guest?
Cupaioli, F. A., Zucca, F. A., Boraschi, D., & Zecca, L. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.05.002 · Cited by 139
Aliphatic polyesters for medical imaging and theranostic applications
Nottelet, B., Darcos, V., & Coudane, J. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.06.023 · Cited by 68
Nanomaterials Based on Functional Polymers for Sensitizing Cancer Radiotherapy
Lin, J., Yin, M., Liu, X., Meng, F., & Luo, L. (2022) · Macromolecular Rapid Communications · doi:10.1002/marc.202200194 · Cited by 18
Metadata
- Authors
- Cheng, Y., Zhao, L., Li, Y., & Xu, T.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2011
- Volume
- 40
- Issue
- 5
- Pages
- 2673
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W2057473750
- Cited by
- 515
- References
- 304
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.